Abstract
Vascular endothelial growth factor (VEGF) has been identified as an important factor for tumour angiogenesis, which is essential for the growth, invasion and metastasis of solid tumours. Significantly increased VEGF level from the primary tumour to the metastatic lesion of ovarian cancers was found in 8 of 30 cases. The 24-month survival rate of the patients with significantly increased VEGF level was extremely poor (0/8 = 0%) in comparison with that of patients with no change in the level (15/22 = 68%) from the primary tumour to the metastatic lesion. This indicates that VEGF may contribute to the advancement of metastatic lesions, and that VEGF level in metastatic lesions may be a prognostic indicator. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF and Brown LF (1996) Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptor in ovarian borderline and malignant neoplasms. Lab Invest 74: 1105–1115
Berkman RA, Merrill MJ, Reinhold WC, Monacci WT, Saxena A, Clark WC, Robertson JT, Ali IU and Oldfield EH (1993) Expression of vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91: 153–159
Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR and Smith SK (1995) Expression of vascular endothelial growth factor and its receptor flt and KDR in ovarian carcinoma. JNCI 87: 506–516
Borgstrom P, Hillan KJ, Sriramarao P and Ferrara N (1996) Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiogenic therapy from intravital videomicroscopy. Cancer Res 56: 4032–4039
Bradford M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 315–323
Denekamp J (1984) Vascular as a target for tumor therapy. Prog Appl Microcirc 4: 28–38
Eisenkop SM, Nalick RH, Wang HJ and Teng NN (1993) Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival. Gynecol Oncol 51: 224–229
FIGO News (1989). Int J Gynecol Obstet 28: 189–193
Folkman J (1985) Tumor angiogenesis. Adv Cancer Res 43: 175–203
Fujimoto J, Ichigo S, Hirose R, Sakaguchi H and Tamaya T (1998) Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine endometrial cancers. Cancer Lett 134: 15–22
Fujimoto J, Sakaguchi H, Hirose R, Ichigo S and Tamaya T (1998) Biological implication of the expression of vascular endothelial growth factor (VEGF) subtypes in ovarian cancers. Cancer 83: 2527–2533
Fujimoto J, Sakaguchi H, Hirose R, Ichigo S and Tamaya T (1999a) Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers. Br J Cancer 80: 827–833
Fujimoto J, Sakaguchi H, Hirose R, Ichigo S and Tamaya T (1999b) Progestins suppress estrogen-induced expression of vascular endothelial growth factor (VEGF) subtypes in uterine endometrial cancer cells. Cancer Lett 141: 63–71
Garrido C, Saule S and Gospodarowicz D (1993) Transcriptional regulation of vascular endothelial growth factor gene expression in ovarian bovine granulosa cells. Growth Factors 8: 109–117
Jackson MR, Carney EW, Lye SJ and Knoxritchie JW (1994) Localization of two angiogenic growth factors (PDECGF and VEGF) in human placentae throughout gestation. Placenta 15: 341–353
Kapp KS, Kapp DS, Poschauko J, Stucklschweiger GF, Hackl A, Pickel H, Petru E and Winter R (1999) The prognostic significance of peritoneal seeding and size of postsurgical residual in patients with stage III epithelial ovarian cancer treated with surgery, chemotherapy, and high-dose radiotherapy. Gynecol Oncol 74: 400–407
Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J and Connolly DT (1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246: 1309–1312
Leung DW, Cachianes G, Kuang WJ, Goeddel DV and Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306–1309
Li XF, Gregory J and Ahmed A (1994) Immunolocalization of vascular endothelial growth factor in human endometrium. Growth Factors 11: 277–282
Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, Carson LF and Ramakrishnan S (1997) Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80: 98–106
Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P and Hicklin DJ (1999) Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59: 5209–5218
Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HS (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983–985
Warren RS, Yuan H, Matli MR, Gillett NA and Ferrara N (1995) Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse of experimental liver metastasis. J Clin Invest 95: 1789–1797
Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N and Jain RK (1996) Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93: 14765–14770
Zhu Z, Rockwell P, Lu D, Kotanides H, Pytowski B, Hicklin DJ, Bohlen P and Witte L (1998) Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res 58: 3209–3214
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Fujimoto, J., Sakaguchi, H., Aoki, I. et al. Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers. Br J Cancer 85, 313–316 (2001). https://doi.org/10.1054/bjoc.2001.1933
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1933
Keywords
This article is cited by
-
Expression of IP-10 related to angiogenesis in uterine cervical cancers
British Journal of Cancer (2007)
-
Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers
Journal of Biomedical Science (2007)
-
Expression of cyclooxygenase-2 related to angiogenesis in uterine cervical cancers
Journal of Biomedical Science (2006)